53亿美元!14倍价差!中国创新药,正在重构国际化新规则

21财经网
13 Jun

21世纪经济报道记者季媛媛 上海报道6月13日,本土创新药企接连宣布了两项重大举措,在全球医药创新的版图上标注了自己的位置。一方面,阿斯利康宣布与石药集团达成战略研究合作。双方将聚焦高优先级靶点,合作推进新型口服候选药物的发现和开发,这些药物有望治疗更多适应证疾病。根据协议,阿斯利康与石药集团同意为多个靶点发现和开发具有多种慢性疾病治疗潜力的临床前候选药物,包括一种用于免疫疾病的临床前小分子口服...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10